1082937-62-9

Basic information

• Product Name: C₂₀H₂₂ClN₃O₅S
• Synonyms: C₂₀H₂₂ClN₃O₅S
• CAS NO: 1082937-62-9
• Molecular Weight: 451.931
• Mol File: 1082937-62-9.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: C₂₀H₂₂ClN₃O₅S(CAS DataBase Reference)
• NIST Chemistry Reference: C₂₀H₂₂ClN₃O₅S(1082937-62-9)
• EPA Substance Registry System: C₂₀H₂₂ClN₃O₅S(1082937-62-9)

Safety Data

• Hazardous Substances Data: 1082937-62-9(Hazardous Substances Data)

Upstream product

• 42518-98-9 5-chlorothiophene-2-carbonyl chloride 
• 1082937-60-7 C₁₅H₂₁N₃O₄ 
• 1082937-58-3 C₂₃H₂₃N₃O₆ 
• 1082937-55-0 C₂₂H₂₅N₃O₅ 
• 395639-03-9 bis(1,1-dimethylethyl)(4-nitrophenyl)imidocarbonate 
• 18437-63-3 tert-butyl N-(4-nitrophenyl)carbamate 
• 100-01-6 4-nitro-aniline 
• 71026-66-9 N-(tert-butoxycarbonyl)-1,4-phenylenediamine 
• 24065-33-6 5-Chlorothiophene-2-carboxylic acid 

Downstream Products

• 482308-02-1 N-{[(5S)-3-(4-aminophenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl}-5-chloro-2-thiophenecarboxamide 
• 1082937-67-4 C₂₂H₂₇ClN₄O₅S 
• 1159610-29-3 5-chloro-N-({(5S)-2-oxo-3-[4-(5,6-dihydro-4H-[1,2,4]-triazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide 
• 1159610-49-7 C₂₂H₂₈ClN₅O₅S 
• 1159610-50-0 C₂₃H₃₀ClN₅O₅S 
• 1159610-51-1 C₂₃H₂₉ClN₄O₅S 
• 1159610-52-2 C₂₃H₃₀ClN₅O₅S 
• 1807455-76-0 C₂₅H₂₄Cl₂N₄O₆S₂ 
• 1151893-81-0 2-{2-[1-(5-chlorothiophen-2-yl)-N-{4-[(5S)-5-{[(5-chlorothiophen-2-yl)formamido]methyl}-2-oxo-1,3-oxazolidin-3-yl]phenyl}formamido]ethoxy}acetic acid 
• 1082936-94-4 C₂₃H₂₀ClN₅O₃S 
• 1082936-75-1 C₂₁H₂₁ClN₄O₃S 
• 1082936-73-9 C₂₀H₂₁ClN₄O₃S 
• 1082936-67-1 C₁₉H₁₉ClN₄O₃S 
• 1083049-80-2 C₁₇H₁₉ClN₄O₃S 

Relevant articles and documents

A related substance [...] F, G synthetic method

The invention provides synthetic methods of related substances F and G of rivaroxaban. With the adoption of the synthetic methods of the related substances F and G of the rivaroxaban, the yield is high, and industrial production and technology transformation are realized easily.

FXA INHIBITORS WITH CYCLIC AMIDOXIME OR CYCLIC AMIDRAZONE AS P4 SUBUNIT, PROCESSES FOR THEIR PREPARATIONS, AND PHARMACEUTICAL COMPOSITIONS AND DERIVATIVES THEREOF

The present invention relates to novel oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone group, pharmaceutically acceptable salts thereof, methods for preparing the same and pharmaceutical compositions comprising the same. The oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone group or the pharmaceutically acceptable salts thereof can be effectively used for the treatment of thromboembolism and tumor as an anticoagulant based on the inhibition of factor Xa.